Revance Therapeutics reported $10.19M in Stock for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Stock Change
Adamas Pharmaceuticals ADMS:US 8.68M 892K
Aerie Pharmaceuticals AERI:US $ 30.06M 0.65M
ALKERMES ALKS:US $ 138.7M 2.62M
Antares Pharma ATRS:US $ 16.49M 2.15M
Biodelivery Sciences International BDSI:US $ 23.08M 4.42M
Bristol Myers Squibb BMY:US $ 2163M 26M
Coherus Biosciences CHRS:US $ 37.58M 58.5M
Eli Lilly And LLY:US $ 3907.4M 82.5M
Endo International Ordinary Shares ENDP:US $ 297.3M 41.15M
Flexion Therapeutics FLXN:US $ 14.67M 2.37M
Horizon Pharma HZNP:US $ 237.43M 21.24M
JAZZ PHA JAZZ:US $ 1137.85M 113.41M
Neurocrine Biosciences NBIX:US $ 25.5M 2.8M
Pacira Pharmaceuticals PCRX:US $ 67.21M 1.94M
Procter & Gamble PG:US $ 6307M 324M
Revance Therapeutics RVNC:US $ 10.19M 5.13M
Supernus Pharmaceuticals SUPN:US $ 60.16M 1.76M
Teva Pharmaceutical Industries TEVA:US $ 4167M 195M
Zogenix ZGNX:US $ 3.5M 0.58M